1 active not recruiting, 1 completed, 1 recruiting, 1 withdrawn. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
Follow TAS-116: new trials by email Literature Review of TAS-116 trials Research Report on TAS-116
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Palbociclib Oral Product, TAS-116 - Advanced Breast Cancer, Treatment-Refractory Solid Tumors | Phase 1 | Withdrawn | Brown University | 2023-09-12 | 2024-09-19 | |
| A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) Pimitespib, Imatinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 | Active not recruiting | Taiho Pharmaceutical Co., Ltd. | 78 | 2021-12-01 | 2026-01-20 |
| AB122 Platform Study AB122, TAS-116, TAS-120 - Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 917 | 2021-06-01 | 2026-08-05 |
| A Study of TAS-116 in Patients With Solid Tumors TAS-116 - Advanced Solid Tumors | Phase 1 | Completed | Taiho Oncology, Inc. | 31 | 2017-07-10 | 2024-09-04 |
Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1) · Sarcoma, Alveolar Soft Part (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Taiho Pharmaceutical Co., Ltd. (2) · Brown University (1) · Taiho Oncology, Inc. (1)
Japan (2) · United States (2) · Australia (1) · China (1) · Italy (1) · Singapore (1) · Taiwan (1) · United Kingdom (1)
Wafik El-Deiry, MD, PhD, FACP (1)
2015 (1)